home > ebr > spring 2007 > adaptive research: new leverage for biotech
European Biopharmaceutical Review

Adaptive Research: New Leverage for Biotech

Michael Rosenberg of Health Decisions discusses the new role of adaptive research in the biotech industry

Adaptive research, the ability to alter clinical studies in progress based on analysis of partial results, is among the most important developments in the biopharmaceutical industry for several decades. For smaller and emerging biopharmaceutical companies, adaptive techniques present an unusual, perhaps unique, opportunity to improve development efficiencies and gain competitive advantage over much larger companies.

Adaptive techniques are the latest and perhaps most significant stage in a transition from big pharma’s long domination of drug discovery and development, to a new and more competitive era in which big pharma is just another player. Advances in technology have lowered barriers to entry, transforming drug development from a capital-intensive, smokestack industry into a technology-leveraged, knowledge-based enterprise. Smaller companies are now on an equal footing with industry giants. Indeed, in many cases, quicker decision-making processes have enabled small companies to lead the way in adopting innovative ideas and methods.

Innovations in drug discovery include combinatorial chemistry, molecular design, RNAi, production of biologics in vivo by recombinant DNA, high-throughput screening, and the use of DNA microarrays. Such innovations have enabled small, ambitious competitors to enter drug discovery, and have yielded vast numbers of candidate drugs and treatments. The leading role played by smaller companies in many of these advances would have been unthinkable just a decade ago.

While innovations in discovery have expanded the number of potential drug candidates, clinical trials remain a chokepoint. They also contribute substantially to development costs estimated at more than US$800 million per drug (1). Even such astronomical spending levels have brought surprisingly few new drugs to market. The US pharma industry’s annual R&D spending reached an all-time high of $40 billion in 2006 but resulted in the approval of only 18 truly new drugs, the lowest number in recent years (2).


The fundamental difference between adaptive capabilities and more traditional development is reliance on a ‘refine as you go’ rather than a ‘black box’ approach. An adaptive design permits adjustments along the way based on experience. This common sense approach stands in stark contrast to the familiar routine of waiting until all the data are available before analysing it and determining success – an approach best summed up as ‘making a guess and keeping your fingers crossed’. Because adaptive requires continuous refinement along the way, these techniques translate to shorter timelines and lower costs. Indeed, continuous adaptive adjustments guarantee success at meeting informational goals at minimum cost in time and money.

Figure 1 illustrates how adaptive approaches continuously acquire knowledge by examining both data and the operational aspects of a study while it is being conducted. In contrast to the usual knowledge gap between the time at which data or study performance metrics (which are most often not available at all, except in the crudest sense, during a study) are available, clean, and in an understandable form, adaptive designs and processes focus on immediately transforming a stream of raw data into meaningful information that can quickly be transformed to knowledge. This capability demands more effective data collection and management than is commonly used.

Adaptive research refers to a broad range of capabilities, all of which relate to what has occurred most recently in a clinical trial. The intellectual groundwork was first laid in 1763 by Thomas Bayes, who gave formal mathematical expression to what many would consider the essence of common sense: continuously updating or revising beliefs in the light of the latest evidence.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Dr Michael Rosenberg is the Founder and CEO of Health Decisions, a global clinical research organisation (CRO) specialising in adaptive clinical research methodologies. He was awarded Ernst & Young’s Entrepreneur of the Year in Health Sciences in 2002, and has led Health Decisions to multiple inclusions in the Inc. 500 fastest growing private companies and the Technology 500 fastest growing technologybased companies in the US. The author of more than 150 scientific articles, Michael serves on advisory groups in business, technology, and medicine. He is Clinical Professor of Obstetrics and Gynecology for the School of Medicine and Adjunct Professor of Epidemiology for the School of Public Health at the University of North Carolina. He practiced emergency medicine for more than 20 years. Michael received his undergraduate and medical degrees from the University of California and his Masters degree in Epidemiology and Biostatistics from Harvard University. He is currently a fellow at the American College of Physicians, the American College of Preventive Medicine, and the American College of Epidemiology.
Dr Michael Rosenberg
Print this page
Send to a friend
Privacy statement
News and Press Releases

Kallik’s Release 6 sets new benchmarks for speed, accuracy and efficiency

Tamworth, UK – 15 June 2019 – Global provider of labelling and artwork management solutions, Kallik, is launching an update to its AMS360 solution – its Release 6, transforming the experience of the business user, whilst defining new benchmarks for speed, accuracy, and efficiency of global labelling and artwork processes.
More info >>

White Papers

Transforming Temperature Data Management Practices to Reduce Labor Costs and Improve Visibility and Control

Berlinger & Co AG

There are a number of temperature monitoring database options available to the biopharma supply chain professional and choosing the right one can significantly improve workflow which will reduce administrative time. This article will provide insight into practices for improving common processes through enhanced database functionality in the areas of managing data loggers by expiry date, storing and retrieving calibration certificates and acknowledging/documenting common temperature excursion events. Additionally, it describes the unique features and benefits of the Berlinger Smartview® data management system. Smartview® is a “Software as a Service” (SaaS) platform designed to efficiently and accurately manage both workflow and data in a regulatory compliant manner (21 CRF Part 11 & Annex 11). This comprehensive temperature data management system ensures reliability, accuracy, security, accessibility, and visibility to supply chain professionals, enhancing Good Distribution Practices (GDP) of temperature sensitive shipments.
More info >>

Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement